BRAIN and NERVE－神経研究の進歩67巻7号

2015年07月発行

増大特集 神経疾患と感染症update

HIV感染症治療の進歩

著者： 松井佑亮¹ 高折晃史¹

所属機関： ¹京都大学大学院医学研究科血液・腫瘍内科

ページ範囲：P.947 - P.959

文献概要

本邦でのHIV（human immunodeficiency virus）感染者，AIDS（acquired immunodeficiency syndrome）患者のこれまでの報告数を合わせると2万人を超えている。ART（antiretroviral therapy）の導入によって患者の生命予後は劇的に改善したが，長期加療による新たな問題が表面化してきた。本稿では，最近数年の抗HIV療法の進歩，そして今後増加することが予測されるHAND（HIV-associated neurocognitive disorders）について述べる。

参考文献

1) 2015年厚生労働省エイズ動向委員会報告, http://api-net.jfap.or.jp/status/index.html

2) Clifford DB: HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 16: 94-98, 2008

3) Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al: HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16, 2011

4) Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799, 2007

5) Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, et al: Neurologic disease burden in tested HIV/AIDS predicts survival: a population-based study. Neurology 75: 1150-1158, 2010

6) Gottlieb MS, Schanker HM, Fan PT, Saxon A, Weisman JD: Pneumocystis Pneumonia Los Angeles. MMWR 30(21): 1-3, 1981

7) Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chmaret S, et al: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 20: 868-871, 1983

8) May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, et al: HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368: 451-458, 2006

9) Barlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, et al: An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 20: 2051-2064, 2006

10) Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, et al: Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 374: 796-806, 2009

11) Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106, 2008

12) Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, et al: Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLOS ONE 6: e22698, 2011

13) De Clercq E: Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307-320, 2009

14) Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, et al: Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361: 2230-2240, 2009

15) D:A:D Study Group; Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426, 2008

16) Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, et al: Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318-330, 2010

17) Smith KY, Patel P, Fine D, Bellos N, Sloan L, et al: Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23: 1547-1556, 2009

18) Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, et al: No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 61: 441-447, 2012

19) Hughes AR, Mosteller RM, Bansal AT, Davies K, Haneline SA, et al: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5: 203-211, 2004

20) Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, et al: Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLOS One 6: e22661, 2011

21) Hill A, Sawyer W, Gazzard B: Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials Jan 10: 1-12, 2009

22) Esnouf R, Ren J, Ross C, Jones Y, Stammers D, et al: Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2: 303-308, 1995

23) Smith PF, DiCenzo R, Morse GD: Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40: 893-905, 2001

24) Herrick TM, Million RP: Tapping the potential of fixed-dose combinations. Nat Rev Drug Discov 6: 513-514, 2007

25) Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, et al: Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378: 229-237, 2011

26) Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, et al: Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378: 238-246, 2011

27) Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, et al: Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reserve transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47: 2550-2560, 2004

28) McDonald C, Uy J, Hu W, Wirtz V, Juethner S, et al: Clinical Significance of Hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 26: 259-264, 2012

29) Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, et al: Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients. AIDS 23: 1679-1688, 2009

30) Koh Y, Matsumi S, Das D, Amano M, Davis DA, et al: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 282: 28709-28720, 2007

31) Hare S, Gupta SS, Vaikov E, Engelman A, Cherepanov P: Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464: 232-236, 2010

32) Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, et al: Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, non-inferiority trial. Lancet Infect Dis 13: 927-935, 2013

33) Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, et al; GS-US-236-0102 Study Team: A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 63: 96-100, 2013

34) Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, et al; GS-236-0103 Study Team: A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 62: 483-486, 2013

35) Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, et al: Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J med 369: 1807-1818, 2013

36) Wohl D, Pozniak A, Thompson M, DeJesus E, Podzamczer D, et al: Tenofovir alafenamide (TAF) in a single-tablet regimen in initial HIV-1 therapy. The 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015). Seattle, February 23-26, 2015．(Abstract 113LB, p156)

37) Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD: When should antiretroviral therapy for HIV be started? BMJ 334: 76-78, 2007

38) Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Eng J Med 360: 1815-1826, 2009

39) When To Start Consortium; Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363, 2009

40) Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505, 2011

41) Daniel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al: Early ART and IPT in HIV-infected African adults with high CD4 count (temprano trial). The 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015). Seattle, February 23-26, 2015．(Abstract 115LB, p157)

42) Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al: CD4＋ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296, 2006

43) Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, et al: The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg BID plus raltegravir (RAL) 400mg BID (ATV＋RAL) in treatment-naíve HIV-infected subjects. The 18th International AIDS Conference (IAC). Vienna, July 18-23 2010．(Abstract THLBB204, p.286)

44) Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, et al: Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-infected patients (ACTG A5262). AIDS 25: 2113-2122, 2011

45) Khetsuriani N, Holman RC, Lamonte-Fowlkes AC, Selik RM, Anderson LJ: Trends in encephalitis-associated deaths in the United States. Epidemiol Infect 135: 583-591, 2007

46) Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al; the CHARTER and HNRC Groups: HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy; differences in rates, nature, and predictors. J Neurovirol 17: 3-16, 2011

47) Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, et al: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096, 2010

48) Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P: HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 25: 561-575, 2011

49) Mind Exchange Working Group: Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the Mind Exchange program. Clin Infect Dis 56: 1004-1017, 2013

50) Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, et al: Human immunodeficiency virus type 1 enters brain microvascular endothelial by macropinocytosis depend-ent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 76: 6689-6700, 2002

51) Hazleton JE, Berman JW, Eugenin EA: Novel mechanisms of central nervous system damage in HIV infection. HIV/AIDS(Auckl) 2: 39-49, 2010

52) Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, et al: Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25: 357-365, 2011

53) Letendre S, Ellis RJ, Deutsch R, Clifford DB, Collier AC, et al: Correlates of time-to-loss-of-viral-response in CSF and plasma in the CHARTER cohort: CPE score predicts CSF suppression. The 17th Conference on Retroviruses and Opportunistic Infections (CROI). San Francisco, February 16-19, 2010 (Abstract 430)

54) EACS (European AIDS Clinical Society): EACS Guidelines. Version 7.1．2014

55) Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, et al: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692-698, 2009